Table 2.

Therapy Outcomes

Case	IHC	FISH	RNA NGS	Variant	DNA NGS	RNA ISH	First-Line Therapy	Documented Progression	Second-Line Therapy	Follow-Up (mo)
1	P	P	EML4 (ex 13)–ALK (ex 20)	1	N	P	Alectinib	N	—	4
2	P	P	EML4 (ex 13)–ALK (ex 20)	1	N	P	Alectinib	N	—	9
3	P	P	EML4 (ex 6)–ALK (ex 20)	3 a/b	N	P	Alectinib	N	—	10
4	P	P	EML4 (ex13)- ALK (ex20)	1	N	P	Alectinib	N	—	10
5	P	P	EML4 (ex 13)–ALK (ex 20)	1	N	P	Alectinib	N	—	6
6	P	P	EML4 (ex 6)–ALK (ex 20)	3 a/b	F1174L	P	Alectinib	@ 4 mo, 12 d	Lorlatinib	6
7	P	P	EML4 (ex 13)–ALK (ex 20)	1	N	P	Alectinib	N	—	13
8	P	P	EML4 (ex 20)–ALK (ex 20)	2	Na	P	Crizotinib	@ 5 mo	Ceritinib	21
9	N	P	N	—	STK11	N	Alectinib	@ 3 mo, 5 d	Pembrolizumab Carboplatin-pemetrexed	18
10	P	P	SLMAP (ex 12/13)–ALK (ex 20)	—	N	P	Crizotinibb	N	—	24

@, at the rate; ex, exon; FISH, fluorescence in situ hybridization; IHC, immunohistochemistry; N, negative; NGS, next-generation sequencing; P, positive; RNA ISH, RNA in situ hybridization; SGA, single-gene analysis.

^aSGA KRAS/EGFR.

^bPatient initially received cisplatin and pemetrexed for four cycles, after RNA NGS testing ALK fusion was identified and patient was switched to crizotinib.